GlaxoSmithKline Holdings (Americas) Inc. - Page 8




                                        - 8 -                                         
          sought to take the depositions of two third-party witnesses.  The           
          two witnesses were 62 and 69 years of age, respectively.  Upon              
          review of the application, we explained that the procedure under            
          Rule 82 was not intended to be used as a discovery device.  See             
          Ash v. Cort, 512 F.2d 909, 911 (3d Cir. 1975).  We also stated              
          that, where an application under Rule 82 suggests that the                  
          proposed deposition might be used for discovery purposes, our               
          decision whether to grant such an application will turn on a                
          weighing of the discovery aspects of the deposition against the             
          applicant’s need to perpetuate testimony.  See Masek v.                     
          Commissioner, 91 T.C. at 1100.  In denying the application in               
          that case, we concluded that the proposed depositions of third-             
          party witnesses reflected “more than a trace of discovery” and              
          the applicant/taxpayer had not shown (through medical records or            
          otherwise) that the proposed deponents’ testimony would likely be           
          lost before trial.  Id. at 1100-1101.                                       
          In our Supplemental Opinion, Masek v. Commissioner, 92 T.C.                 
          814 (1989), we denied the applicant/taxpayer’s motion to                    
          reconsider our earlier opinion, stating that our focus under Rule           
          82 “is directed to the risk that the testimony will be                      
          unavailable when a trial commences, and the applicant must                  
          establish that that risk is significant.”  Id. at 815.                      










Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  Next

Last modified: May 25, 2011